Drugs / 99mTc-MIRC208
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04591652 | Sep 2020 → Aug 2024 | cancer | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-MIRC208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04591652 ↗ |
| Modality | Diagnostic / imaging agent | “This is an open-labeled Single-Photon Emission Computed Tomography/Computed Tomography(SPECT/CT) study to investigate the clinical value of 99mTc-MIRC208 in HER2 status...” NCT04591652 ↗ |
| Route | Intravenous | “after intravenous injection of 14.8 MBq/kg body weight” NCT04591652 ↗ |